Skip to main navigation Skip to search Skip to main content

A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)

  • K. H. Kim
  • , H. J. Lee
  • , S. J. Lee
  • , M. Kim
  • , M. S. Ahn
  • , M. Y. Choi
  • , N. R. Lee
  • , M. Jung
  • , S. J. Shin
  • Yonsei University
  • Chungnam National University
  • Sungkyunkwan University
  • Ewha Womans University
  • Seoul National University
  • Ajou University
  • Inje University

Research output: Contribution to journalJournal articlepeer-review

Original languageEnglish
Pages (from-to)S85-S86
JournalEuropean Journal of Cancer
Volume174
DOIs
StatePublished - 2022.10

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Quacquarelli Symonds(QS) Subject Topics

  • Medicine
  • Biological Sciences

Cite this